Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis

OBJECTIVE: Abatacept is a biological disease-modifying antirheumatic drug (DMARD) used for the treatment of rheumatoid arthritis (RA) and modulates the costimulatory signal by cluster of differentiation (CD)28:CD80/CD86 interaction required for T cell activation. Since CD28-mediated signalling regul...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:RMD Open
Glavni autori: Ghannam, Khetam, Martinez Gamboa, Lorena, Kedor, Claudia, Spengler, Lydia, Kuckelkorn, Ulrike, Häupl, Thomas, Burmester, Gerd, Feist, Eugen
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2020
Teme:
Rheumatoid Arthritis
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7547540/
https://ncbi.nlm.nih.gov/pubmed/32998980
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2020-001248
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items